Kappa opioid agonists reduce oxycodone self-administration in male rhesus monkeys
Rationale Combinations of mu and kappa opioid receptor (KOR) agonists have been proposed as potential analgesic formulations with reduced abuse liability. The current studies extend previous work by investigating the typical KOR agonist, salvinorin A, and the atypical KOR agonist, nalfurafine, as de...
Saved in:
| Published in | Psychopharmacology Vol. 237; no. 5; pp. 1471 - 1480 |
|---|---|
| Main Authors | , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Berlin/Heidelberg
Springer Berlin Heidelberg
01.05.2020
Springer Springer Nature B.V |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Rationale
Combinations of mu and kappa opioid receptor (KOR) agonists have been proposed as potential analgesic formulations with reduced abuse liability. The current studies extend previous work by investigating the typical KOR agonist, salvinorin A, and the atypical KOR agonist, nalfurafine, as deterrents of oxycodone self-administration using a progressive ratio (PR) schedule of reinforcement.
Methods
In separate experiments, adult male rhesus monkeys (
N
= 4/experiment) were trained under a PR schedule of reinforcement to self-administer cocaine (0.1 mg/kg/injection) and saline on alternating days. Oxycodone (0.01–0.1 mg/kg/injection) alone and combined with salvinorin A (experiment 1; 0.006, 0.012 mg/kg/injection) or nalfurafine (experiment 2; 0.0001–0.00032 mg/kg/injection) were tested within the alternating cocaine and saline baseline. The mechanism of nalfurafine’s effects on oxycodone self-administration was investigated via pretreatment with the KOR antagonist, nor-binaltorphimine (nor-BNI; 10 mg/kg; i.m.).
Results
All subjects self-administered oxycodone alone above saline levels at sufficiently large doses, and combining salvinorin A or nalfurafine with oxycodone reduced the mean number of injections per session to saline levels (experiment 1) or to levels that were significantly lower than oxycodone alone (experiment 2). The ability of nalfurafine to reduce oxycodone self-administration was reversed by pretreatment with nor-BNI.
Conclusions
These results demonstrate that KOR agonists, including the clinically used KOR agonist, nalfurafine, can punish self-administration of a prescription opioid analgesic, oxycodone, in rhesus monkeys and that nalfurafine’s punishing effect is KOR-dependent. Combinations of KOR agonists with prescription opioids may have reduced abuse liability. |
|---|---|
| AbstractList | Rationale Combinations of mu and kappa opioid receptor (KOR) agonists have been proposed as potential analgesic formulations with reduced abuse liability. The current studies extend previous work by investigating the typical KOR agonist, salvinorin A, and the atypical KOR agonist, nalfurafine, as deterrents of oxycodone self-administration using a progressive ratio (PR) schedule of reinforcement. Methods In separate experiments, adult male rhesus monkeys (N = 4/experiment) were trained under a PR schedule of reinforcement to self-administer cocaine (0.1 mg/kg/injection) and saline on alternating days. Oxycodone (0.01-0.1 mg/kg/injection) alone and combined with salvinorin A (experiment 1; 0.006, 0.012 mg/kg/injection) or nalfurafine (experiment 2; 0.0001-0.00032 mg/kg/injection) were tested within the alternating cocaine and saline baseline. The mechanism of nalfurafine's effects on oxycodone self-administration was investigated via pretreatment with the KOR antagonist, nor-binaltorphimine (nor-BNI; 10 mg/kg; i.m.). Results All subjects self-administered oxycodone alone above saline levels at sufficiently large doses, and combining salvinorin A or nalfurafine with oxycodone reduced the mean number of injections per session to saline levels (experiment 1) or to levels that were significantly lower than oxycodone alone (experiment 2). The ability of nalfurafine to reduce oxycodone self-administration was reversed by pretreatment with nor-BNI. Conclusions These results demonstrate that KOR agonists, including the clinically used KOR agonist, nalfurafine, can punish self-administration of a prescription opioid analgesic, oxycodone, in rhesus monkeys and that nalfurafine's punishing effect is KOR-dependent. Combinations of KOR agonists with prescription opioids may have reduced abuse liability. Combinations of mu and kappa opioid receptor (KOR) agonists have been proposed as potential analgesic formulations with reduced abuse liability. The current studies extend previous work by investigating the typical KOR agonist, salvinorin A, and the atypical KOR agonist, nalfurafine, as deterrents of oxycodone self-administration using a progressive ratio (PR) schedule of reinforcement. In separate experiments, adult male rhesus monkeys (N = 4/experiment) were trained under a PR schedule of reinforcement to self-administer cocaine (0.1 mg/kg/injection) and saline on alternating days. Oxycodone (0.01-0.1 mg/kg/injection) alone and combined with salvinorin A (experiment 1; 0.006, 0.012 mg/kg/injection) or nalfurafine (experiment 2; 0.0001-0.00032 mg/kg/injection) were tested within the alternating cocaine and saline baseline. The mechanism of nalfurafine's effects on oxycodone self-administration was investigated via pretreatment with the KOR antagonist, nor-binaltorphimine (nor-BNI; 10 mg/kg; i.m.). All subjects self-administered oxycodone alone above saline levels at sufficiently large doses, and combining salvinorin A or nalfurafine with oxycodone reduced the mean number of injections per session to saline levels (experiment 1) or to levels that were significantly lower than oxycodone alone (experiment 2). The ability of nalfurafine to reduce oxycodone self-administration was reversed by pretreatment with nor-BNI. These results demonstrate that KOR agonists, including the clinically used KOR agonist, nalfurafine, can punish self-administration of a prescription opioid analgesic, oxycodone, in rhesus monkeys and that nalfurafine's punishing effect is KOR-dependent. Combinations of KOR agonists with prescription opioids may have reduced abuse liability. Rationale Combinations of mu and kappa opioid receptor (KOR) agonists have been proposed as potential analgesic formulations with reduced abuse liability. The current studies extend previous work by investigating the typical KOR agonist, salvinorin A, and the atypical KOR agonist, nalfurafine, as deterrents of oxycodone self-administration using a progressive ratio (PR) schedule of reinforcement. Methods In separate experiments, adult male rhesus monkeys ( N = 4/experiment) were trained under a PR schedule of reinforcement to self-administer cocaine (0.1 mg/kg/injection) and saline on alternating days. Oxycodone (0.01–0.1 mg/kg/injection) alone and combined with salvinorin A (experiment 1; 0.006, 0.012 mg/kg/injection) or nalfurafine (experiment 2; 0.0001–0.00032 mg/kg/injection) were tested within the alternating cocaine and saline baseline. The mechanism of nalfurafine’s effects on oxycodone self-administration was investigated via pretreatment with the KOR antagonist, nor-binaltorphimine (nor-BNI; 10 mg/kg; i.m.). Results All subjects self-administered oxycodone alone above saline levels at sufficiently large doses, and combining salvinorin A or nalfurafine with oxycodone reduced the mean number of injections per session to saline levels (experiment 1) or to levels that were significantly lower than oxycodone alone (experiment 2). The ability of nalfurafine to reduce oxycodone self-administration was reversed by pretreatment with nor-BNI. Conclusions These results demonstrate that KOR agonists, including the clinically used KOR agonist, nalfurafine, can punish self-administration of a prescription opioid analgesic, oxycodone, in rhesus monkeys and that nalfurafine’s punishing effect is KOR-dependent. Combinations of KOR agonists with prescription opioids may have reduced abuse liability. Combinations of mu and kappa opioid receptor (KOR) agonists have been proposed as potential analgesic formulations with reduced abuse liability. The current studies extend previous work by investigating the typical KOR agonist, salvinorin A, and the atypical KOR agonist, nalfurafine, as deterrents of oxycodone self-administration using a progressive ratio (PR) schedule of reinforcement. In separate experiments, adult male rhesus monkeys (N = 4/experiment) were trained under a PR schedule of reinforcement to self-administer cocaine (0.1 mg/kg/injection) and saline on alternating days. Oxycodone (0.01-0.1 mg/kg/injection) alone and combined with salvinorin A (experiment 1; 0.006, 0.012 mg/kg/injection) or nalfurafine (experiment 2; 0.0001-0.00032 mg/kg/injection) were tested within the alternating cocaine and saline baseline. The mechanism of nalfurafine's effects on oxycodone self-administration was investigated via pretreatment with the KOR antagonist, nor-binaltorphimine (nor-BNI; 10 mg/kg; i.m.). All subjects self-administered oxycodone alone above saline levels at sufficiently large doses, and combining salvinorin A or nalfurafine with oxycodone reduced the mean number of injections per session to saline levels (experiment 1) or to levels that were significantly lower than oxycodone alone (experiment 2). The ability of nalfurafine to reduce oxycodone self-administration was reversed by pretreatment with nor-BNI. These results demonstrate that KOR agonists, including the clinically used KOR agonist, nalfurafine, can punish self-administration of a prescription opioid analgesic, oxycodone, in rhesus monkeys and that nalfurafine's punishing effect is KOR-dependent. Combinations of KOR agonists with prescription opioids may have reduced abuse liability. RationaleCombinations of mu and kappa opioid receptor (KOR) agonists have been proposed as potential analgesic formulations with reduced abuse liability. The current studies extend previous work by investigating the typical KOR agonist, salvinorin A, and the atypical KOR agonist, nalfurafine, as deterrents of oxycodone self-administration using a progressive ratio (PR) schedule of reinforcement.MethodsIn separate experiments, adult male rhesus monkeys (N = 4/experiment) were trained under a PR schedule of reinforcement to self-administer cocaine (0.1 mg/kg/injection) and saline on alternating days. Oxycodone (0.01–0.1 mg/kg/injection) alone and combined with salvinorin A (experiment 1; 0.006, 0.012 mg/kg/injection) or nalfurafine (experiment 2; 0.0001–0.00032 mg/kg/injection) were tested within the alternating cocaine and saline baseline. The mechanism of nalfurafine’s effects on oxycodone self-administration was investigated via pretreatment with the KOR antagonist, nor-binaltorphimine (nor-BNI; 10 mg/kg; i.m.).ResultsAll subjects self-administered oxycodone alone above saline levels at sufficiently large doses, and combining salvinorin A or nalfurafine with oxycodone reduced the mean number of injections per session to saline levels (experiment 1) or to levels that were significantly lower than oxycodone alone (experiment 2). The ability of nalfurafine to reduce oxycodone self-administration was reversed by pretreatment with nor-BNI.ConclusionsThese results demonstrate that KOR agonists, including the clinically used KOR agonist, nalfurafine, can punish self-administration of a prescription opioid analgesic, oxycodone, in rhesus monkeys and that nalfurafine’s punishing effect is KOR-dependent. Combinations of KOR agonists with prescription opioids may have reduced abuse liability. Combinations of mu and kappa opioid receptor (KOR) agonists have been proposed as potential analgesic formulations with reduced abuse liability. The current studies extend previous work by investigating the typical KOR agonist, salvinorin A, and the atypical KOR agonist, nalfurafine, as deterrents of oxycodone self-administration using a progressive ratio (PR) schedule of reinforcement.RATIONALECombinations of mu and kappa opioid receptor (KOR) agonists have been proposed as potential analgesic formulations with reduced abuse liability. The current studies extend previous work by investigating the typical KOR agonist, salvinorin A, and the atypical KOR agonist, nalfurafine, as deterrents of oxycodone self-administration using a progressive ratio (PR) schedule of reinforcement.In separate experiments, adult male rhesus monkeys (N = 4/experiment) were trained under a PR schedule of reinforcement to self-administer cocaine (0.1 mg/kg/injection) and saline on alternating days. Oxycodone (0.01-0.1 mg/kg/injection) alone and combined with salvinorin A (experiment 1; 0.006, 0.012 mg/kg/injection) or nalfurafine (experiment 2; 0.0001-0.00032 mg/kg/injection) were tested within the alternating cocaine and saline baseline. The mechanism of nalfurafine's effects on oxycodone self-administration was investigated via pretreatment with the KOR antagonist, nor-binaltorphimine (nor-BNI; 10 mg/kg; i.m.).METHODSIn separate experiments, adult male rhesus monkeys (N = 4/experiment) were trained under a PR schedule of reinforcement to self-administer cocaine (0.1 mg/kg/injection) and saline on alternating days. Oxycodone (0.01-0.1 mg/kg/injection) alone and combined with salvinorin A (experiment 1; 0.006, 0.012 mg/kg/injection) or nalfurafine (experiment 2; 0.0001-0.00032 mg/kg/injection) were tested within the alternating cocaine and saline baseline. The mechanism of nalfurafine's effects on oxycodone self-administration was investigated via pretreatment with the KOR antagonist, nor-binaltorphimine (nor-BNI; 10 mg/kg; i.m.).All subjects self-administered oxycodone alone above saline levels at sufficiently large doses, and combining salvinorin A or nalfurafine with oxycodone reduced the mean number of injections per session to saline levels (experiment 1) or to levels that were significantly lower than oxycodone alone (experiment 2). The ability of nalfurafine to reduce oxycodone self-administration was reversed by pretreatment with nor-BNI.RESULTSAll subjects self-administered oxycodone alone above saline levels at sufficiently large doses, and combining salvinorin A or nalfurafine with oxycodone reduced the mean number of injections per session to saline levels (experiment 1) or to levels that were significantly lower than oxycodone alone (experiment 2). The ability of nalfurafine to reduce oxycodone self-administration was reversed by pretreatment with nor-BNI.These results demonstrate that KOR agonists, including the clinically used KOR agonist, nalfurafine, can punish self-administration of a prescription opioid analgesic, oxycodone, in rhesus monkeys and that nalfurafine's punishing effect is KOR-dependent. Combinations of KOR agonists with prescription opioids may have reduced abuse liability.CONCLUSIONSThese results demonstrate that KOR agonists, including the clinically used KOR agonist, nalfurafine, can punish self-administration of a prescription opioid analgesic, oxycodone, in rhesus monkeys and that nalfurafine's punishing effect is KOR-dependent. Combinations of KOR agonists with prescription opioids may have reduced abuse liability. |
| Audience | Academic |
| Author | Huskinson, Sally L. Prisinzano, Thomas E. Zamarripa, C. Austin Naylor, Jennifer E. Townsend, E. Andrew Freeman, Kevin B. |
| AuthorAffiliation | a Division of Neurobiology and Behavior Research, Department of Psychiatry and Human Behavior, The University of Mississippi Medical Center, Jackson, MS 39216 b Boozman College of Public Health, University of Arkansas for Medical Sciences, Little Rock, AR 72205 c Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, 23298 d Department of Pharmaceutical Sciences, University of Kentucky, Lexington, KY 40536 |
| AuthorAffiliation_xml | – name: d Department of Pharmaceutical Sciences, University of Kentucky, Lexington, KY 40536 – name: a Division of Neurobiology and Behavior Research, Department of Psychiatry and Human Behavior, The University of Mississippi Medical Center, Jackson, MS 39216 – name: c Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, 23298 – name: b Boozman College of Public Health, University of Arkansas for Medical Sciences, Little Rock, AR 72205 |
| Author_xml | – sequence: 1 givenname: C. Austin surname: Zamarripa fullname: Zamarripa, C. Austin organization: Division of Neurobiology and Behavior Research, Department of Psychiatry and Human Behavior, The University of Mississippi Medical Center – sequence: 2 givenname: Jennifer E. surname: Naylor fullname: Naylor, Jennifer E. organization: Boozman College of Public Health, University of Arkansas for Medical Sciences – sequence: 3 givenname: Sally L. surname: Huskinson fullname: Huskinson, Sally L. organization: Division of Neurobiology and Behavior Research, Department of Psychiatry and Human Behavior, The University of Mississippi Medical Center – sequence: 4 givenname: E. Andrew surname: Townsend fullname: Townsend, E. Andrew organization: Department of Pharmacology and Toxicology, Virginia Commonwealth University – sequence: 5 givenname: Thomas E. surname: Prisinzano fullname: Prisinzano, Thomas E. organization: Department of Pharmaceutical Sciences, University of Kentucky – sequence: 6 givenname: Kevin B. orcidid: 0000-0003-3389-6555 surname: Freeman fullname: Freeman, Kevin B. email: kfreeman@umc.edu organization: Division of Neurobiology and Behavior Research, Department of Psychiatry and Human Behavior, The University of Mississippi Medical Center |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32006048$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kktv1DAQxy1URLeFL8ABReLCJWU8TmLnglRVvEQlhARny-vH1iWxg51U7LfH2y0trVDtgy3P7z8vzxE5CDFYQl5SOKEA_G0GQMpqQKihbTirmydkRRuGNQLHA7ICYKxmtBWH5CjnSyirEc0zcsgQoCv3Ffn2RU2TquLkozeV2sTg85yrZM2ibRV_b3U0JWqV7eBqZUa_syc1-xgqH6pRDbZKFzYvuRpj-Gm3-Tl56tSQ7Yub85j8-PD--9mn-vzrx89np-e1bhs61xxBC94gR9Nbo9YUNQrXayYcUlivQTfagBFgtWBOGA5adQwcGHRrbjg7Ju_2fqdlPVqjbSh5DXJKflRpK6Py8r4l-Au5iVeS075raVccvLlxkOKvxeZZjj5rOwwq2LhkiawF6NuOYUFfP0Av45JCKa9QPadcIPR31KZ0RfrgYomrd07laYfY8pazHXXyH6psY0evS6-dL-_3BK_-LfS2wr-fWADcAzrFnJN1twgFuZsUuZ8UWSZFXk-KbIpIPBBpP1__a0nHD49L2V6aS5ywsemuG4-o_gBYp9Gt |
| CitedBy_id | crossref_primary_10_3389_fnins_2022_964724 crossref_primary_10_1007_s00213_022_06092_x crossref_primary_10_1016_j_pbb_2024_173836 crossref_primary_10_1016_j_neuropharm_2022_109407 crossref_primary_10_1016_j_phrs_2022_106091 crossref_primary_10_1111_bph_15592 crossref_primary_10_1007_s00213_023_06391_x crossref_primary_10_1016_j_drugalcdep_2023_110953 crossref_primary_10_1124_jpet_123_001870 crossref_primary_10_1007_s00213_020_05749_9 crossref_primary_10_1007_s00213_020_05519_7 crossref_primary_10_1016_j_ejmech_2025_117449 crossref_primary_10_1016_j_neubiorev_2024_105713 crossref_primary_10_1124_pharmrev_121_000506 crossref_primary_10_1016_j_expneurol_2021_113602 crossref_primary_10_1038_s41386_022_01444_9 crossref_primary_10_3390_molecules28124848 crossref_primary_10_1021_acschemneuro_0c00407 crossref_primary_10_1021_acschemneuro_0c00608 crossref_primary_10_1007_s00213_023_06486_5 crossref_primary_10_1080_14737159_2023_2190022 crossref_primary_10_1016_j_peptides_2022_170752 crossref_primary_10_1097_FBP_0000000000000581 crossref_primary_10_1016_j_neulet_2025_138154 crossref_primary_10_1111_ijcp_13642 crossref_primary_10_7554_eLife_89993 crossref_primary_10_1021_acsptsci_4c00593 crossref_primary_10_1016_j_neulet_2021_136092 crossref_primary_10_1016_j_pbb_2022_173394 crossref_primary_10_1213_ANE_0000000000005309 crossref_primary_10_7554_eLife_89993_3 crossref_primary_10_1007_s00213_021_05965_x |
| Cites_doi | 10.1038/npp.2010.137 10.1016/j.biopsych.2008.05.029 10.5055/jom.2016.0321 10.1007/s00213-010-1825-8 10.1155/2012/282981 10.1196/annals.1316.050 10.1016/B978-0-12-420118-7.00012-3 10.1016/j.pharmthera.2007.06.011 10.1517/14656566.2014.970175 10.1007/s00213-005-2266-7 10.1124/jpet.301.3.993 10.1007/s00213-017-4652-3 10.1007/s00213-011-2501-3 10.1097/00001756-19940908-00028 10.1016/s0014-2999(01)01194-3 10.1016/0006-8993(95)00306-b 10.1037/1067-1297.12.2.111 10.1254/jjp.85.282 10.1016/j.neuron.2015.08.019 10.1007/s00213-003-1680-y 10.1037/1064-1297.9.2.131 10.1097/FBP.0000000000000136 10.1124/jpet.108.143925 10.1007/s002130000424 10.1037/a0013088 10.1208/aapsj070361 10.1008/s002130000476 10.1124/jpet.104.080101 10.1001/jamanetworkopen.2018.7621 10.1358/dot.2009.45.5.1362067 10.1038/s41386-019-0423-7 10.15585/mmwr.mm6450a3 10.1097/FBP.0b013e3283512c1e 10.5055/jom.2018.0476 10.1126/scisignal.aai8441 10.1016/0165-0270(95)00153-0 10.1007/s00213-012-2912-9 10.1007/s00213-013-3396-y 10.1007/s00213-009-1637 10.1007/BF02246019 10.1007/s002130000457 10.3389/fphar.2019.00407 10.1007/s00213-014-3436-2 10.1007/s00213-009-1705-2 10.1016/j.pbb.2009.09.002 10.1111/j.1749-6632-2000.tb06678.x 10.1016/j.cellsig.2017.01.016 10.1007/128_2010_74 10.1002/syn.20191 10.1097/FBP.0000000000000436 10.1038/npp.2013.171 10.1016/j.tips.2016.11.002 10.1016/s0091-3057(00)00478-0 10.1016/j.biopsych.2012.06.012 10.1037/pha0000098 10.1124/jpet.118.255661 10.1002/0471142301.ns0921s32 |
| ContentType | Journal Article |
| Copyright | Springer-Verlag GmbH Germany, part of Springer Nature 2020 COPYRIGHT 2020 Springer Springer-Verlag GmbH Germany, part of Springer Nature 2020. |
| Copyright_xml | – notice: Springer-Verlag GmbH Germany, part of Springer Nature 2020 – notice: COPYRIGHT 2020 Springer – notice: Springer-Verlag GmbH Germany, part of Springer Nature 2020. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QG 7QR 7RV 7TK 7X7 7XB 88E 88G 8AO 8FD 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FR3 FYUFA GHDGH GNUQQ K9. KB0 M0S M1P M2M NAPCQ P64 PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS PSYQQ Q9U 7X8 5PM |
| DOI | 10.1007/s00213-020-05473-4 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Animal Behavior Abstracts Chemoreception Abstracts Nursing & Allied Health Database Neurosciences Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Psychology Database (Alumni) ProQuest Pharma Collection Technology Research Database Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials - QC ProQuest Central ProQuest One ProQuest Central Korea Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Health & Medical Collection Medical Database (ProQuest) Psychology Database Nursing & Allied Health Premium Biotechnology and BioEngineering Abstracts ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Psychology ProQuest Central Student Technology Research Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection Chemoreception Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Psychology Journals (Alumni) Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest Psychology Journals ProQuest One Academic UKI Edition Animal Behavior Abstracts ProQuest Nursing & Allied Health Source (Alumni) Engineering Research Database ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE ProQuest One Psychology MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1432-2072 |
| EndPage | 1480 |
| ExternalDocumentID | PMC7196516 A622575739 32006048 10_1007_s00213_020_05473_4 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: National Institute on Drug Abuse grantid: R01DA039167; DA018151; DA045011; F31DA048586 funderid: http://dx.doi.org/10.13039/100000026 – fundername: NIDA NIH HHS grantid: F31 DA048586 – fundername: NIDA NIH HHS grantid: DA045011 – fundername: NIDA NIH HHS grantid: R01 DA039167 – fundername: NIDA NIH HHS grantid: R01DA039167 – fundername: NIDA NIH HHS grantid: DA018151 – fundername: NIDA NIH HHS grantid: R01 DA018151 – fundername: NIDA NIH HHS grantid: R01 DA045011 – fundername: NIDA NIH HHS grantid: F31DA048586 |
| GroupedDBID | -4W -BR .55 3SX 40D 40E 95. 95~ ABMNI AGWIL ALMA_UNASSIGNED_HOLDINGS KOW N2Q R9- RHV SBY SOJ X7M ~EX AAYXX CITATION --- -Y2 .86 .GJ .VR 04C 06C 06D 0R~ 0VY 123 199 1N0 1SB 2.D 203 28- 29P 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2QV 2VQ 2~H 30V 36B 3O- 4.4 406 408 409 53G 5QI 5RE 5VS 67N 67Z 6NX 78A 7RV 7X7 88E 8AO 8FI 8FJ 8TC 8UJ 95- 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANXM AANZL AAPKM AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAYIU AAYQN AAYTO AAYZH ABAKF ABBBX ABBRH ABBXA ABDBE ABDBF ABDZT ABECU ABFSG ABFTV ABHLI ABHQN ABIPD ABIVO ABJNI ABJOX ABKCH ABKTR ABMQK ABNWP ABPLI ABQBU ABQSL ABRTQ ABSXP ABTEG ABTHY ABTKH ABTMW ABULA ABUWG ABWNU ABXPI ACAOD ACBXY ACDTI ACGFS ACHSB ACHXU ACIWK ACKNC ACMDZ ACMLO ACNCT ACOKC ACOMO ACPIV ACPRK ACSTC ACUHS ACZOJ ADBBV ADHHG ADHIR ADHKG ADIMF ADJJI ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADYPR ADZKW AEBTG AEFIE AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AEZWR AFBBN AFDZB AFEXP AFFNX AFGCZ AFHIU AFKRA AFLOW AFOHR AFQWF AFRAH AFWTZ AFZKB AGAYW AGDGC AGGDS AGJBK AGMZJ AGQEE AGQMX AGQPQ AGRTI AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHPBZ AHSBF AHWEU AHYZX AIAKS AIGIU AIIXL AILAN AITGF AIXLP AJBLW AJRNO AJZVZ AKMHD ALIPV ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG ATHPR AVWKF AXYYD AYFIA AZFZN AZQEC B-. B0M BA0 BBWZM BDATZ BENPR BGNMA BKEYQ BMSDO BPHCQ BSONS BVXVI CAG CCPQU CGR COF CS3 CSCUP CUY CVF DDRTE DL5 DNIVK DPUIP DU5 DWQXO DXH EAD EAP EBC EBD EBLON EBS ECM EIF EIHBH EIOEI EJD EMB EMK EMOBN EN4 EPAXT EPL EPS ESBYG ESX EX3 F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNUQQ GNWQR GQ7 GQ8 GXS H13 HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IAO ICJ IHE IHR IJ- IKXTQ IMOTQ INH INR IPY ITM IWAJR IXC IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KPH LAS LLZTM M1P M2M M4Y MA- MK0 N9A NAPCQ NB0 NDZJH NPM NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM P19 P2P PF- PHGZM PHGZT PJZUB PPXIY PQQKQ PROAC PSQYO PSYQQ PT4 PT5 Q2X QOK QOR QOS R4E R89 R9I RIG RNI ROL RPX RRX RSV RZK S16 S1Z S26 S27 S28 S3A S3B SAP SBL SCLPG SDH SDM SHX SISQX SJYHP SNE SNPRN SNX SOHCF SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZN T13 T16 TN5 TSG TSK TSV TUC TUS U2A U9L UAP UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WH7 WIP WJK WK6 WK8 WOW XOL YLTOR YQJ YYP Z45 ZGI ZMTXR ZOVNA ZY4 ~8M 3V. 7QG 7QR 7TK 7XB 8FD 8FK FR3 K9. P64 PKEHL PQEST PQUKI PRINS Q9U 7X8 PUEGO 5PM |
| ID | FETCH-LOGICAL-c541t-720c874272d9edab12c28f9c38f210bb0c4cd0d80ec83f8d70ca630f0d2fb7d73 |
| IEDL.DBID | 7X7 |
| ISSN | 0033-3158 1432-2072 |
| IngestDate | Thu Aug 21 14:07:09 EDT 2025 Sun Aug 24 03:23:31 EDT 2025 Sat Aug 16 11:51:34 EDT 2025 Wed Mar 19 00:51:54 EDT 2025 Sat Mar 08 18:34:52 EST 2025 Mon Jul 21 05:48:24 EDT 2025 Tue Jul 01 04:16:56 EDT 2025 Thu Apr 24 23:09:37 EDT 2025 Fri Feb 21 02:34:16 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Keywords | Punishment Self-administration Rhesus monkey Oxycodone Kappa opioid agonist |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c541t-720c874272d9edab12c28f9c38f210bb0c4cd0d80ec83f8d70ca630f0d2fb7d73 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0003-3389-6555 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/7196516 |
| PMID | 32006048 |
| PQID | 2397178209 |
| PQPubID | 47309 |
| PageCount | 10 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_7196516 proquest_miscellaneous_2350095632 proquest_journals_2397178209 gale_infotracmisc_A622575739 gale_infotracacademiconefile_A622575739 pubmed_primary_32006048 crossref_primary_10_1007_s00213_020_05473_4 crossref_citationtrail_10_1007_s00213_020_05473_4 springer_journals_10_1007_s00213_020_05473_4 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2020-05-01 |
| PublicationDateYYYYMMDD | 2020-05-01 |
| PublicationDate_xml | – month: 05 year: 2020 text: 2020-05-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Berlin/Heidelberg |
| PublicationPlace_xml | – name: Berlin/Heidelberg – name: Germany – name: Heidelberg |
| PublicationTitle | Psychopharmacology |
| PublicationTitleAbbrev | Psychopharmacology |
| PublicationTitleAlternate | Psychopharmacology (Berl) |
| PublicationYear | 2020 |
| Publisher | Springer Berlin Heidelberg Springer Springer Nature B.V |
| Publisher_xml | – name: Springer Berlin Heidelberg – name: Springer – name: Springer Nature B.V |
| References | Schmidt, Schmidt, Butelman, Harding, Tidgewell, Murry, Kreek, Prisinzano (CR52) 2005; 58 Banks, Negus (CR3) 2017; 38 Nagase, Fujii (CR37) 2011; 299 Cosgrove, Carroll (CR11) 2004; 12 Rudd, Aleshire, Zibbell, Gladden (CR47) 2016; 64 Cosgrove, Carroll (CR10) 2002; 301 Morani, Kivell, Prisinzano, Schenk (CR34) 2009; 94 Brust, Morgenweck, Kim, Rose, Locke, Schmid, Zhou, Stahl, Cameron, Scarry, Aube, Jones, Martin, Bohn (CR4) 2016; 9 Collins, D’Addario, Izenwasser (CR9) 2001; 426 Raffa, Pergolizzi, Muniz, Taylor, Pergolizzi (CR43) 2012; 2012 Mello, Negus (CR32) 2000; 909 Freeman, McMaster, Roma, Woolverton (CR15) 2014; 231 Nakao, Mochizuki (CR38) 2009; 45 CR2 Wee, Anderson, Baumann, Rothman, Blough, Woolverton (CR60) 2005; 313 Chefer, Backman, Gigante, Shippenberg (CR7) 2013; 38 Friedmann, Marsman, de Kater, Burns, Webster (CR17) 2018; 14 Holtz, Carroll (CR22) 2015; 26 CR41 Freeman, Naylor, Prisinzano, Woolverton (CR16) 2014; 231 Richardson, Roberts (CR45) 1996; 66 Rowlett, Massey, Kleven, Woolverton (CR46) 1996; 125 Prisinzano, Tidgewell, Harding (CR42) 2005; 7 MacLean, Johnson, Reissig, Prisinzano, Griffiths (CR30) 2013; 226 Villesen, Banning, Petersen, Weinelt, Poulsen, Hansen, Christrup (CR58) 2007; 3 Lynch, Carroll (CR28) 2001; 9 Mastropietro, Omidian (CR31) 2015; 16 Minervini, Osteicoechea, Casalez, France (CR33) 2019; 30 Kivell, Ewald, Prisinzano (CR26) 2014; 69 Glick, Maisonneuve, Raucci, Archer (CR18) 1995; 681 Townsend, Naylor, Negus, Edwards, Qureshi, McLendon, McCurdy, Kapanda, do Carmo, Fernanda, Hall, Sufka, Freeman (CR56) 2017; 234 CR13 Jones, Kaye, Kaye, Urman (CR24) 2016; 12 Morani, Schenk, Prisinzano, Kivell (CR35) 2012; 23 Ruedi-Bettschen, Rowlett, Spealman, Platt (CR48) 2010; 210 Chen, Larochelle, Weaver, Lietz, Mueller, Mercaldo, Wakeman, Freedberg, Raphel, Knudsen, Pandharipande, Chhatwal (CR8) 2019; 2 Freeman, Woolverton (CR14) 2009; 207 Schenk, Partridge, Shippenberg (CR51) 2000; 151 Shippenberg, Zapata, Chefer (CR53) 2007; 116 Chavkin (CR6) 2011; 36 Schenk, Partridge (CR50) 2001; 68 Lynch, Nicholson, Dance, Morgan, Foley (CR29) 2010; 60 Negus, Schrode, Stevenson (CR40) 2008; 16 Al-Hasani, McCall, Shin, Gomez, Schmitz, Bernardi, Pyo, Park, Marcinkiewcz, Crowley, Krashes, Lowell, Kash, Rogers, Bruchas (CR1) 2015; 87 Hasebe, Kawai, Suzuki, Kawamura, Tanaka, Narita, Nagase, Suzuki (CR20) 2004; 1-25 Wee, Koob (CR59) 2010; 210 Butelman, Ko, Sobczyk-Kojiro, Mosberg, Van Bemmel, Zernig, Woods (CR5) 1998; 285 Heidbreder, Shippenberg (CR21) 1994; 5 Ko, Husbands (CR27) 2009; 328 CR25 Schattauer, Kuhar, Song, Chavkin (CR49) 2017; 32 CR23 Endoh, Tajima, Izumimoto, Suzuki, Saitoh, Suzuki (CR12) 2001; 85 Ranganathan, Schnakenberg, Skosnik, Cohen, Pittman, Sewell, D’Souza (CR44) 2012; 72 Tomasiewicz, Todtenkopf, Chartoff, Cohen, Carlezon (CR55) 2008; 64 Negus (CR39) 2005; 181 Gross, Kaski, Schmidt, Cogan, Boyt, Wix, Schroer, McElligott, Siderovski, Setola (CR19) 2019; 44 Todtenkopf, Marcus, Portoghese, Carlezon (CR54) 2004; 172 Woolverton, Freeman, Myerson, Green (CR62) 2012; 220 Vanderschuren, Schoffelmeer, Wardeh, De Vries (CR57) 2000; 150 Wilcox, Rowlett, Paul, Ordway, Woolverton (CR61) 2000; 153 Mores, Cummins, Cassell, van Rijn (CR36) 2019; 10 K Hasebe (5473_CR20) 2004; 1-25 LJ Vanderschuren (5473_CR57) 2000; 150 HH Villesen (5473_CR58) 2007; 3 KA MacLean (5473_CR30) 2013; 226 SS Schattauer (5473_CR49) 2017; 32 JD Gross (5473_CR19) 2019; 44 ML Banks (5473_CR3) 2017; 38 AS Morani (5473_CR35) 2012; 23 5473_CR13 MD Schmidt (5473_CR52) 2005; 58 C Chavkin (5473_CR6) 2011; 36 KP Cosgrove (5473_CR11) 2004; 12 S Schenk (5473_CR50) 2001; 68 S Schenk (5473_CR51) 2000; 151 TF Brust (5473_CR4) 2016; 9 5473_CR2 SS Negus (5473_CR40) 2008; 16 HC Tomasiewicz (5473_CR55) 2008; 64 K Nakao (5473_CR38) 2009; 45 S Wee (5473_CR60) 2005; 313 NA Holtz (5473_CR22) 2015; 26 WJ Lynch (5473_CR29) 2010; 60 5473_CR23 AS Morani (5473_CR34) 2009; 94 TS Shippenberg (5473_CR53) 2007; 116 MS Todtenkopf (5473_CR54) 2004; 172 5473_CR25 T Endoh (5473_CR12) 2001; 85 NR Richardson (5473_CR45) 1996; 66 VI Chefer (5473_CR7) 2013; 38 MC Ko (5473_CR27) 2009; 328 MR Jones (5473_CR24) 2016; 12 N Friedmann (5473_CR17) 2018; 14 KM Wilcox (5473_CR61) 2000; 153 KB Freeman (5473_CR16) 2014; 231 KB Freeman (5473_CR14) 2009; 207 EA Townsend (5473_CR56) 2017; 234 WJ Lynch (5473_CR28) 2001; 9 R Al-Hasani (5473_CR1) 2015; 87 SS Negus (5473_CR39) 2005; 181 M Ranganathan (5473_CR44) 2012; 72 JK Rowlett (5473_CR46) 1996; 125 SL Collins (5473_CR9) 2001; 426 NK Mello (5473_CR32) 2000; 909 RA Rudd (5473_CR47) 2016; 64 S Wee (5473_CR59) 2010; 210 BM Kivell (5473_CR26) 2014; 69 H Nagase (5473_CR37) 2011; 299 DJ Mastropietro (5473_CR31) 2015; 16 KP Cosgrove (5473_CR10) 2002; 301 RB Raffa (5473_CR43) 2012; 2012 KB Freeman (5473_CR15) 2014; 231 KL Mores (5473_CR36) 2019; 10 5473_CR41 ER Butelman (5473_CR5) 1998; 285 V Minervini (5473_CR33) 2019; 30 CA Heidbreder (5473_CR21) 1994; 5 D Ruedi-Bettschen (5473_CR48) 2010; 210 Q Chen (5473_CR8) 2019; 2 TE Prisinzano (5473_CR42) 2005; 7 SD Glick (5473_CR18) 1995; 681 WL Woolverton (5473_CR62) 2012; 220 |
| References_xml | – volume: 36 start-page: 369 year: 2011 end-page: 370 ident: CR6 article-title: The therapeutic potential of kappa-opioids for treatment of pain and addiction publication-title: Neuropsychopharmacol doi: 10.1038/npp.2010.137 – volume: 64 start-page: 982 year: 2008 end-page: 988 ident: CR55 article-title: The kappa-opioid agonist U69,593 blocks cocaine-induced enhancement of brain stimulation reward publication-title: Biol Psychiatry doi: 10.1016/j.biopsych.2008.05.029 – volume: 12 start-page: 101 year: 2016 end-page: 107 ident: CR24 article-title: The emerging therapeutic roles of kappa-opioid agonists publication-title: J Opioid Manag doi: 10.5055/jom.2016.0321 – volume: 210 start-page: 121 year: 2010 end-page: 135 ident: CR59 article-title: The role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of abuse publication-title: Psychopharmacology doi: 10.1007/s00213-010-1825-8 – volume: 2012 start-page: 282981 year: 2012 ident: CR43 article-title: Designing opioids that deter abuse publication-title: Pain Res Treat doi: 10.1155/2012/282981 – volume: 1-25 start-page: 404 year: 2004 end-page: 413 ident: CR20 article-title: Possible pharmacotherapy of the opioid kappa receptor agonist for drug dependence publication-title: Ann N Y Acad Sci doi: 10.1196/annals.1316.050 – volume: 69 start-page: 481 year: 2014 end-page: 511 ident: CR26 article-title: Salvinorin A analogs and other κ-opioid receptor compounds as treatments for cocaine abuse publication-title: Adv Pharmacol doi: 10.1016/B978-0-12-420118-7.00012-3 – volume: 116 start-page: 306 year: 2007 end-page: 321 ident: CR53 article-title: Dynorphin and the pathophysiology of drug addiction publication-title: Pharmacol Ther doi: 10.1016/j.pharmthera.2007.06.011 – volume: 16 start-page: 305 year: 2015 end-page: 323 ident: CR31 article-title: Abuse-deterrent formulations: part 2: commercial products and proprietary technologies publication-title: Expert Opin Pharmacother doi: 10.1517/14656566.2014.970175 – volume: 181 start-page: 244 year: 2005 end-page: 252 ident: CR39 article-title: Effects of punishment on choice between cocaine and food in rhesus monkeys publication-title: Psychopharmacology doi: 10.1007/s00213-005-2266-7 – volume: 301 start-page: 993 year: 2002 end-page: 1002 ident: CR10 article-title: Effects of bremazocine on self-administration of smoked cocaine base and orally delivered ethanol, phencyclidine, saccharin, and food in rhesus monkeys: a behavioral economic analysis publication-title: J Pharmacol Exp Ther doi: 10.1124/jpet.301.3.993 – volume: 234 start-page: 2597 year: 2017 end-page: 2605 ident: CR56 article-title: Effects of nalfurafine on oxycodone reinforcement, thermal antinociception, and respiration: modeling an abuse-deterrent opioid analgesic in rats publication-title: Psychopharmacology doi: 10.1007/s00213-017-4652-3 – ident: CR25 – volume: 3 start-page: 961 year: 2007 end-page: 967 ident: CR58 article-title: Pharmacokinetics of morphine and oxycodone following intravenous administration in elderly patients publication-title: Ther Clin Risk Manag – volume: 220 start-page: 509 year: 2012 end-page: 517 ident: CR62 article-title: Suppression of cocaine self-administration in monkeys: effects of delayed punishment publication-title: Psychopharmacology doi: 10.1007/s00213-011-2501-3 – volume: 5 start-page: 1797 year: 1994 end-page: 1800 ident: CR21 article-title: U-69593 prevents cocaine sensitization by normalizing basal accumbens dopamine publication-title: Neuroreport doi: 10.1097/00001756-19940908-00028 – volume: 426 start-page: 25 year: 2001 end-page: 34 ident: CR9 article-title: Effects of kappa-opioid receptor agonists on long-term cocaine use and dopamine neurotransmission publication-title: Eur J Pharmacol doi: 10.1016/s0014-2999(01)01194-3 – volume: 681 start-page: 147 year: 1995 end-page: 152 ident: CR18 article-title: Kappa opioid inhibition of morphine and cocaine self-administration in rats publication-title: Brain Res doi: 10.1016/0006-8993(95)00306-b – volume: 12 start-page: 111 year: 2004 end-page: 117 ident: CR11 article-title: Differential effects of bremazocine on oral phencyclidine (PCP) self-administration in male and female rhesus monkeys publication-title: Exp Clin Psychopharmacol doi: 10.1037/1067-1297.12.2.111 – volume: 85 start-page: 282 year: 2001 end-page: 290 ident: CR12 article-title: TRK-820, a selective -opioid agonist, produces potent antinociception in cynomolgus monkeys publication-title: Jpn J Pharmacol doi: 10.1254/jjp.85.282 – volume: 87 start-page: 1063 year: 2015 end-page: 1077 ident: CR1 article-title: Distinct subpopulations of nucleus accumbens dynorphin neurons drive aversion and reward publication-title: Neuron doi: 10.1016/j.neuron.2015.08.019 – volume: 172 start-page: 463 year: 2004 end-page: 470 ident: CR54 article-title: Effects of kappa-opioid receptor ligands on intracranial self-stimulation in rats publication-title: Psychopharmacology doi: 10.1007/s00213-003-1680-y – volume: 9 start-page: 131 year: 2001 end-page: 143 ident: CR28 article-title: Regulation of drug intake publication-title: Exp Clin Psychopharmacol doi: 10.1037/1064-1297.9.2.131 – volume: 26 start-page: 393 year: 2015 end-page: 397 ident: CR22 article-title: Cocaine self-administration punished by intravenous histamine in adolescent and adult rats publication-title: Behav Pharmacol doi: 10.1097/FBP.0000000000000136 – volume: 328 start-page: 193 year: 2009 end-page: 200 ident: CR27 article-title: Effects of atypical kappa-opioid receptor agonists on intrathecal morphine-induced itch and analgesia in primates publication-title: J Pharmacol Exp Ther doi: 10.1124/jpet.108.143925 – volume: 150 start-page: 35 year: 2000 end-page: 44 ident: CR57 article-title: Dissociable effects of the kappa-opioid receptor agonists bremazocine, U69593, and U50488H on locomotor activity and long-term behavioral sensitization induced by amphetamine and cocaine publication-title: Psychopharmacology doi: 10.1007/s002130000424 – volume: 60 start-page: 177 year: 2010 end-page: 188 ident: CR29 article-title: Animal models of substance abuse and addiction: implications for science, animal welfare, and society publication-title: Comp Med – volume: 16 start-page: 386 year: 2008 end-page: 399 ident: CR40 article-title: Mu/kappa opioid interactions in rhesus monkeys: implications for analgesia and abuse liability publication-title: Exp Clin Psychopharmacol doi: 10.1037/a0013088 – volume: 7 start-page: E592 year: 2005 end-page: E599 ident: CR42 article-title: Kappa opioids as potential treatments for stimulant dependence publication-title: AAPS J doi: 10.1208/aapsj070361 – volume: 151 start-page: 85 year: 2000 end-page: 90 ident: CR51 article-title: Reinstatement of extinguished drug-taking behavior in rats: effect of the kappa-opioid receptor agonist, U69593 publication-title: Psychopharmacology doi: 10.1008/s002130000476 – volume: 313 start-page: 848 year: 2005 end-page: 854 ident: CR60 article-title: Relationship between the serotonergic activity and reinforcing effects of a series of amphetamine analogs publication-title: J Pharmacol Exp Ther doi: 10.1124/jpet.104.080101 – ident: CR2 – volume: 2 start-page: e187621 year: 2019 ident: CR8 article-title: Prevention of prescription opioid misuse and projected overdose deaths in the United States publication-title: JAMA Netw Open doi: 10.1001/jamanetworkopen.2018.7621 – volume: 45 start-page: 323 year: 2009 end-page: 329 ident: CR38 article-title: Nalfurafine hydrochloride: a new drug for the treatment of uremic pruritus in hemodialysis patients publication-title: Drugs Today doi: 10.1358/dot.2009.45.5.1362067 – volume: 44 start-page: 1728 year: 2019 end-page: 1741 ident: CR19 article-title: Role of RGS12 in the differential regulation of kappa opioid receptor-dependent signaling and behavior publication-title: Neuropsychopharmacol doi: 10.1038/s41386-019-0423-7 – volume: 64 start-page: 1378 year: 2016 end-page: 1382 ident: CR47 article-title: Increases in drug and opioid overdose deaths--United States, 2000-2014 publication-title: MMWR Morb Mortal Wkly Rep doi: 10.15585/mmwr.mm6450a3 – volume: 23 start-page: 162 year: 2012 end-page: 170 ident: CR35 article-title: A single injection of a novel kappa opioid receptor agonist salvinorin A attenuates the expression of cocaine-induced behavioral sensitization in rats publication-title: Behav Pharmacol doi: 10.1097/FBP.0b013e3283512c1e – volume: 14 start-page: 437 year: 2018 end-page: 443 ident: CR17 article-title: A nasal abuse potential randomized clinical trial of REMOXY(R) ER, a high-viscosity extended-release oxycodone formulation publication-title: J Opioid Manag doi: 10.5055/jom.2018.0476 – volume: 9 start-page: ra117 year: 2016 ident: CR4 article-title: Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria publication-title: Sci Signal doi: 10.1126/scisignal.aai8441 – volume: 66 start-page: 1 year: 1996 end-page: 11 ident: CR45 article-title: Progressive ratio schedules in drug self-administration studies in rats: a method to evaluate reinforcing efficacy publication-title: J Neurosci Methods doi: 10.1016/0165-0270(95)00153-0 – volume: 285 start-page: 595 year: 1998 end-page: 601 ident: CR5 article-title: Kappa-opioid receptor binding populations in rhesus monkey brain: relationship to an assay of thermal antinociception publication-title: J Pharmacol Exp Ther – ident: CR23 – volume: 226 start-page: 381 year: 2013 end-page: 392 ident: CR30 article-title: Dose-related effects of salvinorin a in humans: dissociative, hallucinogenic, and memory effects publication-title: Psychopharmacology doi: 10.1007/s00213-012-2912-9 – volume: 231 start-page: 2395 year: 2014 end-page: 2403 ident: CR15 article-title: Assessment of the effects of contingent histamine injections on the reinforcing effectiveness of cocaine using behavioral economic and progressive-ratio designs publication-title: Psychopharmacology doi: 10.1007/s00213-013-3396-y – volume: 207 start-page: 99 year: 2009 end-page: 106 ident: CR14 article-title: Self-administration of cocaine and nicotine mixtures by rhesus monkeys publication-title: Psychopharmacology doi: 10.1007/s00213-009-1637 – volume: 125 start-page: 361 year: 1996 end-page: 370 ident: CR46 article-title: Parametric analysis of cocaine self-administration under a progressive-ratio schedule in rhesus monkeys publication-title: Psychopharmacology doi: 10.1007/BF02246019 – volume: 153 start-page: 139 year: 2000 end-page: 147 ident: CR61 article-title: On the relationship between the dopamine transporter and the reinforcing effects of local anesthetics in rhesus monkeys: practical and theoretical concerns publication-title: Psychopharmacology doi: 10.1007/s002130000457 – volume: 10 start-page: 407 year: 2019 ident: CR36 article-title: A review of the therapeutic potential of recently developed G protein-biased kappa agonist publication-title: Front Pharmacol doi: 10.3389/fphar.2019.00407 – volume: 231 start-page: 2751 year: 2014 end-page: 2758 ident: CR16 article-title: Assessment of the kappa opioid agonist, salvinorin a, as a punisher of drug self-administration in monkeys publication-title: Psychopharmacology doi: 10.1007/s00213-014-3436-2 – volume: 210 start-page: 169 year: 2010 end-page: 177 ident: CR48 article-title: Attenuation of cocaine-induced reinstatement of drug seeking in squirrel monkeys: kappa opioid and serotonergic mechanisms publication-title: Psychopharmacology doi: 10.1007/s00213-009-1705-2 – volume: 94 start-page: 244 year: 2009 end-page: 249 ident: CR34 article-title: Effect of kappa-opioid receptor agonists U69593, U50488H, spiradoline and salvinorin a on cocaine-induced drug-seeking in rats publication-title: Pharmacol Biochem Behav doi: 10.1016/j.pbb.2009.09.002 – volume: 909 start-page: 104 year: 2000 end-page: 132 ident: CR32 article-title: Interactions between kappa opioid agonists and cocaine. Preclinical studies publication-title: Ann N Y Acad Sci doi: 10.1111/j.1749-6632-2000.tb06678.x – volume: 32 start-page: 59 year: 2017 end-page: 65 ident: CR49 article-title: Nalfurafine is a G-protein biased agonist having significantly greater bias at the human than rodent form of the kappa opioid receptor publication-title: Cell Signal doi: 10.1016/j.cellsig.2017.01.016 – ident: CR13 – volume: 299 start-page: 29 year: 2011 end-page: 62 ident: CR37 article-title: Opioids in preclinical and clinical trials publication-title: Top Curr Chem doi: 10.1007/128_2010_74 – volume: 58 start-page: 208 year: 2005 end-page: 210 ident: CR52 article-title: Pharmacokinetics of the plant-derived k-opioid hallucinogen salvinorin A in nonhuman primates publication-title: Synapse doi: 10.1002/syn.20191 – volume: 30 start-page: 335 year: 2019 end-page: 342 ident: CR33 article-title: Punishment and reinforcement by opioid receptor agonists in a choice procedure in rats publication-title: Behav Pharmacol doi: 10.1097/FBP.0000000000000436 – volume: 38 start-page: 2623 year: 2013 end-page: 2631 ident: CR7 article-title: Kappa opioid receptors on dopaminergic neurons are necessary for kappa-mediated place aversion publication-title: Neuropsychopharmacol doi: 10.1038/npp.2013.171 – ident: CR41 – volume: 38 start-page: 181 year: 2017 end-page: 194 ident: CR3 article-title: Insights from preclinical choice models on treating drug addiction publication-title: Trends Pharmacol Sci doi: 10.1016/j.tips.2016.11.002 – volume: 68 start-page: 629 year: 2001 end-page: 634 ident: CR50 article-title: Effect of the kappa-opioid receptor agonist, U69593, on reinstatement of extinguished amphetamine self-administration behavior publication-title: Pharmacol Biochem Behav doi: 10.1016/s0091-3057(00)00478-0 – volume: 72 start-page: 871 year: 2012 end-page: 879 ident: CR44 article-title: Dose-related behavioral, subjective, endocrine, and psychophysiological effects of the kappa opioid agonist Salvinorin a in humans publication-title: Biol Psychiatry doi: 10.1016/j.biopsych.2012.06.012 – volume: 45 start-page: 323 year: 2009 ident: 5473_CR38 publication-title: Drugs Today doi: 10.1358/dot.2009.45.5.1362067 – volume: 909 start-page: 104 year: 2000 ident: 5473_CR32 publication-title: Ann N Y Acad Sci doi: 10.1111/j.1749-6632-2000.tb06678.x – ident: 5473_CR23 doi: 10.1037/pha0000098 – volume: 313 start-page: 848 year: 2005 ident: 5473_CR60 publication-title: J Pharmacol Exp Ther doi: 10.1124/jpet.104.080101 – volume: 210 start-page: 169 year: 2010 ident: 5473_CR48 publication-title: Psychopharmacology doi: 10.1007/s00213-009-1705-2 – volume: 44 start-page: 1728 year: 2019 ident: 5473_CR19 publication-title: Neuropsychopharmacol doi: 10.1038/s41386-019-0423-7 – volume: 299 start-page: 29 year: 2011 ident: 5473_CR37 publication-title: Top Curr Chem doi: 10.1007/128_2010_74 – volume: 681 start-page: 147 year: 1995 ident: 5473_CR18 publication-title: Brain Res doi: 10.1016/0006-8993(95)00306-b – volume: 14 start-page: 437 year: 2018 ident: 5473_CR17 publication-title: J Opioid Manag doi: 10.5055/jom.2018.0476 – volume: 12 start-page: 101 year: 2016 ident: 5473_CR24 publication-title: J Opioid Manag doi: 10.5055/jom.2016.0321 – volume: 150 start-page: 35 year: 2000 ident: 5473_CR57 publication-title: Psychopharmacology doi: 10.1007/s002130000424 – volume: 26 start-page: 393 year: 2015 ident: 5473_CR22 publication-title: Behav Pharmacol doi: 10.1097/FBP.0000000000000136 – volume: 68 start-page: 629 year: 2001 ident: 5473_CR50 publication-title: Pharmacol Biochem Behav doi: 10.1016/s0091-3057(00)00478-0 – volume: 64 start-page: 1378 year: 2016 ident: 5473_CR47 publication-title: MMWR Morb Mortal Wkly Rep doi: 10.15585/mmwr.mm6450a3 – volume: 12 start-page: 111 year: 2004 ident: 5473_CR11 publication-title: Exp Clin Psychopharmacol doi: 10.1037/1067-1297.12.2.111 – volume: 9 start-page: 131 year: 2001 ident: 5473_CR28 publication-title: Exp Clin Psychopharmacol doi: 10.1037/1064-1297.9.2.131 – volume: 72 start-page: 871 year: 2012 ident: 5473_CR44 publication-title: Biol Psychiatry doi: 10.1016/j.biopsych.2012.06.012 – volume: 32 start-page: 59 year: 2017 ident: 5473_CR49 publication-title: Cell Signal doi: 10.1016/j.cellsig.2017.01.016 – volume: 2 start-page: e187621 year: 2019 ident: 5473_CR8 publication-title: JAMA Netw Open doi: 10.1001/jamanetworkopen.2018.7621 – volume: 2012 start-page: 282981 year: 2012 ident: 5473_CR43 publication-title: Pain Res Treat doi: 10.1155/2012/282981 – volume: 94 start-page: 244 year: 2009 ident: 5473_CR34 publication-title: Pharmacol Biochem Behav doi: 10.1016/j.pbb.2009.09.002 – ident: 5473_CR13 – volume: 30 start-page: 335 year: 2019 ident: 5473_CR33 publication-title: Behav Pharmacol doi: 10.1097/FBP.0000000000000436 – volume: 87 start-page: 1063 year: 2015 ident: 5473_CR1 publication-title: Neuron doi: 10.1016/j.neuron.2015.08.019 – volume: 1-25 start-page: 404 year: 2004 ident: 5473_CR20 publication-title: Ann N Y Acad Sci doi: 10.1196/annals.1316.050 – volume: 58 start-page: 208 year: 2005 ident: 5473_CR52 publication-title: Synapse doi: 10.1002/syn.20191 – volume: 207 start-page: 99 year: 2009 ident: 5473_CR14 publication-title: Psychopharmacology doi: 10.1007/s00213-009-1637 – volume: 16 start-page: 305 year: 2015 ident: 5473_CR31 publication-title: Expert Opin Pharmacother doi: 10.1517/14656566.2014.970175 – volume: 38 start-page: 2623 year: 2013 ident: 5473_CR7 publication-title: Neuropsychopharmacol doi: 10.1038/npp.2013.171 – volume: 151 start-page: 85 year: 2000 ident: 5473_CR51 publication-title: Psychopharmacology doi: 10.1008/s002130000476 – volume: 220 start-page: 509 year: 2012 ident: 5473_CR62 publication-title: Psychopharmacology doi: 10.1007/s00213-011-2501-3 – volume: 85 start-page: 282 year: 2001 ident: 5473_CR12 publication-title: Jpn J Pharmacol doi: 10.1254/jjp.85.282 – volume: 125 start-page: 361 year: 1996 ident: 5473_CR46 publication-title: Psychopharmacology doi: 10.1007/BF02246019 – ident: 5473_CR25 doi: 10.1124/jpet.118.255661 – volume: 69 start-page: 481 year: 2014 ident: 5473_CR26 publication-title: Adv Pharmacol doi: 10.1016/B978-0-12-420118-7.00012-3 – volume: 5 start-page: 1797 year: 1994 ident: 5473_CR21 publication-title: Neuroreport doi: 10.1097/00001756-19940908-00028 – volume: 301 start-page: 993 year: 2002 ident: 5473_CR10 publication-title: J Pharmacol Exp Ther doi: 10.1124/jpet.301.3.993 – volume: 231 start-page: 2395 year: 2014 ident: 5473_CR15 publication-title: Psychopharmacology doi: 10.1007/s00213-013-3396-y – ident: 5473_CR2 – volume: 64 start-page: 982 year: 2008 ident: 5473_CR55 publication-title: Biol Psychiatry doi: 10.1016/j.biopsych.2008.05.029 – volume: 153 start-page: 139 year: 2000 ident: 5473_CR61 publication-title: Psychopharmacology doi: 10.1007/s002130000457 – ident: 5473_CR41 doi: 10.1002/0471142301.ns0921s32 – volume: 60 start-page: 177 year: 2010 ident: 5473_CR29 publication-title: Comp Med – volume: 36 start-page: 369 year: 2011 ident: 5473_CR6 publication-title: Neuropsychopharmacol doi: 10.1038/npp.2010.137 – volume: 328 start-page: 193 year: 2009 ident: 5473_CR27 publication-title: J Pharmacol Exp Ther doi: 10.1124/jpet.108.143925 – volume: 210 start-page: 121 year: 2010 ident: 5473_CR59 publication-title: Psychopharmacology doi: 10.1007/s00213-010-1825-8 – volume: 38 start-page: 181 year: 2017 ident: 5473_CR3 publication-title: Trends Pharmacol Sci doi: 10.1016/j.tips.2016.11.002 – volume: 285 start-page: 595 year: 1998 ident: 5473_CR5 publication-title: J Pharmacol Exp Ther – volume: 172 start-page: 463 year: 2004 ident: 5473_CR54 publication-title: Psychopharmacology doi: 10.1007/s00213-003-1680-y – volume: 426 start-page: 25 year: 2001 ident: 5473_CR9 publication-title: Eur J Pharmacol doi: 10.1016/s0014-2999(01)01194-3 – volume: 16 start-page: 386 year: 2008 ident: 5473_CR40 publication-title: Exp Clin Psychopharmacol doi: 10.1037/a0013088 – volume: 23 start-page: 162 year: 2012 ident: 5473_CR35 publication-title: Behav Pharmacol doi: 10.1097/FBP.0b013e3283512c1e – volume: 231 start-page: 2751 year: 2014 ident: 5473_CR16 publication-title: Psychopharmacology doi: 10.1007/s00213-014-3436-2 – volume: 181 start-page: 244 year: 2005 ident: 5473_CR39 publication-title: Psychopharmacology doi: 10.1007/s00213-005-2266-7 – volume: 7 start-page: E592 year: 2005 ident: 5473_CR42 publication-title: AAPS J doi: 10.1208/aapsj070361 – volume: 10 start-page: 407 year: 2019 ident: 5473_CR36 publication-title: Front Pharmacol doi: 10.3389/fphar.2019.00407 – volume: 226 start-page: 381 year: 2013 ident: 5473_CR30 publication-title: Psychopharmacology doi: 10.1007/s00213-012-2912-9 – volume: 234 start-page: 2597 year: 2017 ident: 5473_CR56 publication-title: Psychopharmacology doi: 10.1007/s00213-017-4652-3 – volume: 3 start-page: 961 year: 2007 ident: 5473_CR58 publication-title: Ther Clin Risk Manag – volume: 116 start-page: 306 year: 2007 ident: 5473_CR53 publication-title: Pharmacol Ther doi: 10.1016/j.pharmthera.2007.06.011 – volume: 66 start-page: 1 year: 1996 ident: 5473_CR45 publication-title: J Neurosci Methods doi: 10.1016/0165-0270(95)00153-0 – volume: 9 start-page: ra117 year: 2016 ident: 5473_CR4 publication-title: Sci Signal doi: 10.1126/scisignal.aai8441 |
| SSID | ssj0000484 ssj0068394 |
| Score | 2.4747458 |
| Snippet | Rationale
Combinations of mu and kappa opioid receptor (KOR) agonists have been proposed as potential analgesic formulations with reduced abuse liability. The... Combinations of mu and kappa opioid receptor (KOR) agonists have been proposed as potential analgesic formulations with reduced abuse liability. The current... Rationale Combinations of mu and kappa opioid receptor (KOR) agonists have been proposed as potential analgesic formulations with reduced abuse liability. The... RationaleCombinations of mu and kappa opioid receptor (KOR) agonists have been proposed as potential analgesic formulations with reduced abuse liability. The... |
| SourceID | pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1471 |
| SubjectTerms | Agonists Analgesics Analgesics, Opioid - administration & dosage Animal experimentation Animals Behavior, Addictive - drug therapy Behavior, Addictive - psychology Biomedical and Life Sciences Biomedicine Central nervous system depressants Cocaine Cocaine - administration & dosage Deterrents Diterpenes, Clerodane - administration & dosage Dose-Response Relationship, Drug Drug self-administration Experiments Injection Liability (Law) Macaca mulatta Male Morphinans - administration & dosage Naltrexone - administration & dosage Naltrexone - analogs & derivatives Narcotic Antagonists - administration & dosage Narcotics Neurophysiology Neurosciences Opioid receptors (type kappa) Opioid receptors (type mu) Original Investigation Oxycodone Oxycodone - administration & dosage Pharmacology/Toxicology Psychiatry Receptors, Opioid, kappa - agonists Reinforcement, Psychology Remifentanil Salvinorin A Self Administration Spiro Compounds - administration & dosage |
| SummonAdditionalLinks | – databaseName: SpringerLink Journals (ICM) dbid: U2A link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3di9QwEA96gvgien5VT4kg54NbSJMmaR8X8TiUkxNu4d5Ckqbewtku211w_3tn-rV2UcHHMpOSZj7TyfxCyLtSO5eFvIiFzHmcahtiKz2enLLeIZ5WzrB3-OKrOl-kn6_ldd8U1gyn3YeSZOupx2Y3DEdYc8TibapFnN4l9yTu3UGLF3y-978ptl52DwrifwfELLCNTGZ938yfXziJTYce-rcQdXh88qCG2oams0fkYZ9T0nmnBI_JnVAdk_sXfdX8mJxedvjUuxm92rdbNTN6Si_3yNW7J-TbF7taWVqvlvWyoPZ7jbC6DV0jvGug9c-dh01sFWgTbsvYTmB36bKiP-BT6PomNNuGgnaDe2ieksXZp6uP53F_50LsZZpsYs2Zz2C7rHmRh8K6hHuelbkXWQmbQ-eYT33BiowFn4kyKzTzVglWsoKXThdaPCNHFczkBaEKuCA5lCovbaqA2SmvNKSQTpZMKxuRZFht43tAcrwX49aMUMqthAxIyLQSMmlEPoxjVh0cxz-536MQDdoqvNnbvuUA5oeoV2auwJtpqUUekZMJJ9iYn5IHNTC9jTeGQyqXINwgkN-OZByJ59aqUG-RR2ISqwSPyPNOa8Z5C_ybA8oaET3Rp5EBkb-nlGp50yKAa8SBTFREZoPm7af19-V4-X_sr8gD3hlHzJITcrRZb8NryMA27k1rcL8AJcYkyA priority: 102 providerName: Springer Nature |
| Title | Kappa opioid agonists reduce oxycodone self-administration in male rhesus monkeys |
| URI | https://link.springer.com/article/10.1007/s00213-020-05473-4 https://www.ncbi.nlm.nih.gov/pubmed/32006048 https://www.proquest.com/docview/2397178209 https://www.proquest.com/docview/2350095632 https://pubmed.ncbi.nlm.nih.gov/PMC7196516 |
| Volume | 237 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3di9NAEB_0DsQX0fMreh4ryPlgg5uv3eRJWmk9PK5UuUJ9CpvNxiucSWxasP-9M0mamoL3FMJOwn7M1-7M_BbgXSaTJDRRantB5Nq-VMZWgabMKaUTwtOKONUOX03Fxdz_uggW7YFb1aZV7nRirajTQtMZ-UcXDadD4G7Rp_K3TbdGUXS1vULjPhwTdBmldMmF3Gtin4owmxeBnkADyexRQVkQthU0dR0dWToKZ1Jc2Jee7fes1KGu_sdYHSZSHkRTayM1eQyPWu-SDRt2eAL3TH4CD67a-PkJnM8apOrtgF3vC6-qATtnsz2G9fYpfLtUZalYUS6LZcrUz4IAdiu2IqBXw4o_W43b2dywytxmtuoB8LJlzn7hUNjqxlSbiuHEoaKonsF8Mr7-fGG3ty_YOvCdtS1drkPcOEs3jUyqEsfVbphF2gsz3CYmCde-TnkacqNDLwtTybUSHs946maJTKX3HI5y7MlLYAKp0E0MRJQpXyBxIrSQ6EwmQcalUBY4u9mOdQtNTjdk3MYdqHK9QjGuUFyvUOxb8KH7pmyAOe6kfk-LGJPU4p-1aosPsH-EfxUPBeo1GUgvsuC0R4nSpvvNOzaIW2mv4j1vWvC2a6YvKYMtN8WGaAJyZ4XnWvCi4Zqu3x6d6yCzWiB7_NQREAZ4vyVf3tRY4JIQIR1hwWDHeftu_X86Xt09itfw0G2EwebOKRytVxvzBn2vdXJWC9gZHA8no9GUnl9-XI7xORpPZ9-xde4O_wKony2c |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEB6VVIJeEJRHDQUWCcqBWPi5ax8QKtAqJU0UUCr15q7Xaxqp2CFOBPlT_EZm_EhwJHrr0drZ1drz9ux8C_AqFXEc6DAxXT90TE9IbUpf0ckpqWLC0wot6h0eDHnvzPty7p9vwZ-mF4aOVTY2sTTUSa7oH_k7Bx2nTeBu4YfpT5NujaLqanOFRiUWfb38hSlb8f7kM_L3teMcH40_9cz6VgFT-Z49N4VjqQATQuEkoU5kbDvKCdJQuUGK6U8cW8pTiZUEllaBmwaJsJTkrpVaiZPGIhEurnsLtj0XU5kObH88Go6-rW2_R22f1QPH2KMCgXaphc0P6p6dsnOPfCsVUKkS7QnX9Fp-cdM7_OMeN49ubtRvS7d4fA_u1vEsO6wE8D5s6WwXbg_qiv0uHIwqbOxll43XrV5Flx2w0Ro1e_kAvvbldCpZPp3kk4TJ7zlB-hZsRtCymuW_lwoT6EyzQl-lpmxB_rJJxn7gq7DZpS4WBUNWoWkqHsLZjXDmEXQy3MkeMI5UGJj6PEylx5E45ooLDF9jP7UElwbYzdeOVA2GTndyXEUrGOeSQxFyKCo5FHkGvF3NmVZQINdSvyEmRmQncGUl63YH3B8hbkWHHC2p8IUbGrDfokT9Vu3hRgyi2r4U0VobDHi5GqaZdGYu0_mCaHwKoLnrGPC4kprVvl36k4TCaoBoydOKgFDH2yPZ5LJEHxeEQWlzA7qN5K239f_P8eT6t3gBd3rjwWl0ejLsP4Udp1IM07L3oTOfLfQzjPzm8fNa3Rhc3LSG_wWcbmcM |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwED-NIU28IBhfgQFGgvFAoyVxYicPCE2MaqNsKtIm9S04jsMqjSQ0raD_Gn8dd_loSSX2tsfIZ8vJfTp39zPA60wmSWii1OZB5Nm-VMZWgabKKaUTwtOKHOodPj0Txxf-50kw2YI_XS8MlVV2NrE21Gmh6R_5gYeO0yVwt-gga8sixkfDD-VPm26Qokxrd51GIyIjs_yFx7fq_ckR8vqN5w0_nX88ttsbBmwd-O7clp6jQzwcSi-NTKoS19NemEWahxkehZLE0b5OnTR0jA55FqbS0UpwJ3NSL0tkKjmuewtuSx64pGNyItdewKcG0OZBYBTSwEFzamYLwrZ7p-7hIy9LqVTKSfuS237PQ276iX8c5WYR50Ymt3aQw3twt41s2WEjivdhy-S7sHPa5u53YX_coGQvB-x83fRVDdg-G6_xs5cP4OtIlaViRTktpilT3wsC963YjEBmDSt-LzUepXPDKnOV2aoH_sumOfuBr8Jml6ZaVAwZhUaqeggXN8KXR7Cd406eABNIhSFqIKJM-QKJE6GFxEA2CTJHCmWB233tWLew6HQ7x1W8AnSuORQjh-KaQ7FvwbvVnLIBBbmW-i0xMSaLgStr1TY-4P4Ieys-FGhTZSB5ZMFejxI1XfeHOzGIW0tTxWu9sODVaphmUvVcbooF0QQUSgvuWfC4kZrVvjn9U0JhtUD25GlFQPjj_ZF8elnjkEtCo3SFBYNO8tbb-v_neHr9W7yEHdTr-MvJ2egZ3PEavbAddw-257OFeY4h4Dx5Uesag283rdx_AYDQadw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Kappa+opioid+agonists+reduce+oxycodone+self-administration+in+male+rhesus+monkeys&rft.jtitle=Psychopharmacology&rft.au=Austin%2C+Zamarripa+C&rft.au=Naylor%2C+Jennifer+E&rft.au=Huskinson%2C+Sally+L&rft.au=Andrew%2C+Townsend+E&rft.date=2020-05-01&rft.pub=Springer+Nature+B.V&rft.issn=0033-3158&rft.eissn=1432-2072&rft.volume=237&rft.issue=5&rft.spage=1471&rft.epage=1480&rft_id=info:doi/10.1007%2Fs00213-020-05473-4&rft.externalDBID=HAS_PDF_LINK |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0033-3158&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0033-3158&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0033-3158&client=summon |